{"success":true,"data":{"pressRelease":{"id":"164578","rtpr_id":"nPn1BRGKha-20261008","ticker":"AVXL","exchange":"NASDAQ","all_tickers":["AVXL"],"title":"SueWallSt Reminds Shareholders of a Lead Plaintiff Deadline of November 30, 2026 in Anavex Life Sciences Corp. Lawsuit - AVXL","author":"PR Newswire","published_at":"2026-10-08T14:11:03.024Z","article_body":"SueWallSt Reminds Shareholders of a Lead Plaintiff Deadline of November 30, 2026 in Anavex Life Sciences Corp. Lawsuit - AVXL\nPR Newswire\n\nNEW YORK, Oct. 8, 2026\n\nThe Red Flags: What Insiders Allegedly Knew Before Shareholders Did. Anavex\nnow says its Board reviews and executive certifications could operate on\nincomplete information, and it has told investors to rely only on its revised\nclinical trial descriptions.\n\nNEW YORK  , Oct. 8, 2026 /PRNewswire/ -- SueWallSt announces that a\nsecurities class action has been filed against Anavex Life Sciences Corp.\n(NASDAQ: AVXL) in the United States District Court for the Southern District\nof New York. You may be affected if you purchased AVXL securities between\nNovember 26, 2025 and August 28, 2026 and lost money on your Anavex\ninvestment. Submit your information\n(https://edge.prnewswire.com/c/link/?t=0&l=en&o=4791990-14&h=4257353793&u=https%3A%2F%2Fsuewallst.com%2Flawsuits%2Fanavex-life-sciences-corp-class-action-lawsuit-avxl%3Fprid%3D210234%26wire%3D4&a=Submit+your+information)\n or contact Joseph E. Levi, Esq. at jlevi@SueWallSt.com\n(mailto:jlevi@SueWallSt.com)  or (888) SueWallSt.\n\nAVXL shares fell $0.19, or 6.35%, to close at $2.80 on August 31, 2026. The\ndecline followed Anavex's report that its controls were not effective at four\nstraight period-ends, from September 30, 2025 through June 30, 2026. Lead\nplaintiff applications must be submitted by November 30, 2026.\n\nAnavex Red Flags Insiders Allegedly Knew Before the Market Did\n\nThe action alleges that Anavex described its controls as effective during a\nperiod when regulatory, clinical, and non-financial information reached the\nBoard, the Audit Committee, and the principal financial officer primarily\nthrough the former chief executive. Plaintiffs contend this alleged\nconcealment kept shareholders from seeing a control gap. The Company later\ndescribed that gap as a material weakness rooted in an entity-level control\ndeficiency.\n\nWhat Investors Were Allegedly Not Told\n\n * November 25, 2025 and February 9, 2026: The annual and first-quarter reports\ncalled disclosure controls effective. The lawsuit contends these statements\nwere inaccurate when made.\n * August 28, 2026: The amended annual report stated that management review,\nlegal review, Audit Committee review, Board review, and executive\ncertifications \"could operate while relying on an incomplete information\npopulation.\"\n * The same day: Anavex told investors to \"rely only on the descriptions of our\nclinical trials\" in its new quarterly report \"and on any future updated\ninformation.\"\n * FDA and EMA context: The Company said it would seek FDA guidance on how far\nefficacy data from past trials can be applied to ANAVEX 2-73. It also\nreferenced a CHMP Withdrawal Assessment Report on its EMA submission in early\nAlzheimer's disease.\n * Paused programs: Development of ANAVEX 3-71, ANAVEX 1-41, and ANAVEX 1066 was\nhalted after a strategy review under new leadership.\nThe Rights AVXL Purchasers Hold Now\n\nThe complaint asserts claims under Sections 10(b) and 20(a) of the Securities\nExchange Act of 1934. In practical terms, these claims give Class Period\npurchasers a way to seek damages tied to allegedly misleading public\nstatements. Class members do not need to serve as lead plaintiff, or still own\ntheir shares, to remain part of the proposed class.\n\nInvestors with substantial losses may ask the Court to appoint them to oversee\nthe case on behalf of all AVXL purchasers.\n\n\"The timeline raises important questions about when certain risks were known\ninternally versus when they were disclosed to the investing public. Anavex has\nnow stated that its review and certification controls could operate on an\nincomplete information population. Investors who bought AVXL during the Class\nPeriod are entitled to understand what that may mean for them.\" -- Joseph E.\nLevi, Esq.\n\nAct now. Click here to learn more\n(https://edge.prnewswire.com/c/link/?t=0&l=en&o=4791990-14&h=649358680&u=https%3A%2F%2Fsuewallst.com%2Flawsuits%2Fanavex-life-sciences-corp-class-action-lawsuit-avxl%3Fprid%3D210234%26wire%3D4&a=Act+now.+Click+here+to+learn+more)\nor call (888) SueWallSt.\n\nWHY SUEWALLST: SueWallSt is powered by Levi & Korsinsky LLP. Levi &\nKorsinsky LLP has established itself as a nationally-recognized securities\nlitigation firm that has secured hundreds of millions of dollars for aggrieved\nshareholders and built a track record of winning high-stakes cases. The firm\nhas extensive expertise representing investors in complex securities\nlitigation and a team of over 70 employees to serve our clients. For seven\nyears in a row, Levi & Korsinsky has ranked in ISS Securities Class Action\nServices' Top 50 Report as one of the top securities litigation firms in the\nUnited States.\n\nFrequently Asked Questions About the AVXL Lawsuit\n\nQ: Who is eligible to join the AVXL investor lawsuit? A: Investors who\npurchased AVXL stock or securities between November 26, 2025 and August 28,\n2026 and suffered financial losses may be eligible. Eligibility is based on\npurchase date and documented losses -- not on whether you still hold the\nshares.\n\nQ: How much did AVXL stock drop? A: The filed complaint tracks three\nallegedly related stock declines: first of Shares fell $0.02, or about 0.59%\non May 6, 2026, a further $0.18, or 5.55%, on May 12, 2026, and a final $0.19,\nor 6.35%, settling at $2.80 per share on August 31, 2026. Investors who\npurchased shares during the Class Period at allegedly artificially inflated\nprices and suffered losses may be eligible to seek compensation.\n\nQ: What specific misstatements does the AVXL lawsuit allege? A: The complaint\nalleges that Anavex made materially false or misleading statements during the\nClass Period about the effectiveness of its internal control over financial\nreporting, its disclosure controls, and its regulatory risks. According to the\ncomplaint, these statements omitted alleged misconduct by its former CEO.\n\nQ: What is a lead plaintiff and why does it matter? A: A lead plaintiff is\nthe investor appointed by the court to represent the entire class. Lead\nplaintiffs are typically investors with the largest documented losses. Being\nappointed does not increase individual recovery but gives direct oversight of\nhow the case is run.\n\nQ: What happens after I submit my information? A: Your trading history will\nbe reviewed at no cost for an initial assessment of your potential\neligibility.\n\nQ: What if I already sold my AVXL shares -- can I still recover losses? A:\nYes. Eligibility is based on when you purchased, not whether you still hold\nthe shares. Investors who bought during the Class Period and sold at a loss\nmay still be eligible to participate.\n\nQ: Do I need to go to court or give testimony? A: No. The overwhelming\nmajority of class members never appear in court or give depositions. If there\nis a settlement or recovery, eligible class members generally submit a claim\nform to seek their portion.\n\nQ: What does it cost me to participate? A: There is no upfront cost to submit\nyour information and review whether you may be eligible to recover. Should you\nchoose to participate in the securities class action, they are generally\nhandled on a contingency basis, with any attorneys' fees and expenses subject\nto court approval.\n\nCONTACT:\\\nLevi & Korsinsky, LLP\\\nJoseph E. Levi, Esq.\\\n33 Whitehall Street, 27th Floor\\\nNew York, NY 10004\\\njlevi@SueWallSt.com (mailto:jlevi@SueWallSt.com) \\\nTel: (888) SueWallSt\\\nFax: (212) 363-7171\n\nAttorney Advertising. Prior results do not guarantee similar outcomes.\n\nView original content to download\nmultimedia:https://www.prnewswire.com/news-releases/suewallst-reminds-shareholders-of-a-lead-plaintiff-deadline-of-november-30-2026-in-anavex-life-sciences-corp-lawsuit---avxl-302902194.html\n(https://www.prnewswire.com/news-releases/suewallst-reminds-shareholders-of-a-lead-plaintiff-deadline-of-november-30-2026-in-anavex-life-sciences-corp-lawsuit---avxl-302902194.html)\n\nSOURCE SueWallSt.com\n\n\n\nPhoto: \nhttps://mmx.prnewswire.com/media/MS1812443/suewallst-logo-1-Logo.jpg?id=OA2993000\n\nCopyright (c) 2026 PR Newswire Association,LLC. All Rights Reserved.","article_body_html":"","raw_payload":{"data":{"id":"nPn1BRGKha-20261008","title":"SueWallSt Reminds Shareholders of a Lead Plaintiff Deadline of November 30, 2026 in Anavex Life Sciences Corp. Lawsuit - AVXL","author":"PR Newswire","ticker":"AVXL","created":"2026-10-08T14:11:03.024Z","tickers":["AVXL"],"exchange":"NASDAQ","article_body":"SueWallSt Reminds Shareholders of a Lead Plaintiff Deadline of November 30, 2026 in Anavex Life Sciences Corp. Lawsuit - AVXL\nPR Newswire\n\nNEW YORK, Oct. 8, 2026\n\nThe Red Flags: What Insiders Allegedly Knew Before Shareholders Did. Anavex\nnow says its Board reviews and executive certifications could operate on\nincomplete information, and it has told investors to rely only on its revised\nclinical trial descriptions.\n\nNEW YORK  , Oct. 8, 2026 /PRNewswire/ -- SueWallSt announces that a\nsecurities class action has been filed against Anavex Life Sciences Corp.\n(NASDAQ: AVXL) in the United States District Court for the Southern District\nof New York. You may be affected if you purchased AVXL securities between\nNovember 26, 2025 and August 28, 2026 and lost money on your Anavex\ninvestment. Submit your information\n(https://edge.prnewswire.com/c/link/?t=0&l=en&o=4791990-14&h=4257353793&u=https%3A%2F%2Fsuewallst.com%2Flawsuits%2Fanavex-life-sciences-corp-class-action-lawsuit-avxl%3Fprid%3D210234%26wire%3D4&a=Submit+your+information)\n or contact Joseph E. Levi, Esq. at jlevi@SueWallSt.com\n(mailto:jlevi@SueWallSt.com)  or (888) SueWallSt.\n\nAVXL shares fell $0.19, or 6.35%, to close at $2.80 on August 31, 2026. The\ndecline followed Anavex's report that its controls were not effective at four\nstraight period-ends, from September 30, 2025 through June 30, 2026. Lead\nplaintiff applications must be submitted by November 30, 2026.\n\nAnavex Red Flags Insiders Allegedly Knew Before the Market Did\n\nThe action alleges that Anavex described its controls as effective during a\nperiod when regulatory, clinical, and non-financial information reached the\nBoard, the Audit Committee, and the principal financial officer primarily\nthrough the former chief executive. Plaintiffs contend this alleged\nconcealment kept shareholders from seeing a control gap. The Company later\ndescribed that gap as a material weakness rooted in an entity-level control\ndeficiency.\n\nWhat Investors Were Allegedly Not Told\n\n * November 25, 2025 and February 9, 2026: The annual and first-quarter reports\ncalled disclosure controls effective. The lawsuit contends these statements\nwere inaccurate when made.\n * August 28, 2026: The amended annual report stated that management review,\nlegal review, Audit Committee review, Board review, and executive\ncertifications \"could operate while relying on an incomplete information\npopulation.\"\n * The same day: Anavex told investors to \"rely only on the descriptions of our\nclinical trials\" in its new quarterly report \"and on any future updated\ninformation.\"\n * FDA and EMA context: The Company said it would seek FDA guidance on how far\nefficacy data from past trials can be applied to ANAVEX 2-73. It also\nreferenced a CHMP Withdrawal Assessment Report on its EMA submission in early\nAlzheimer's disease.\n * Paused programs: Development of ANAVEX 3-71, ANAVEX 1-41, and ANAVEX 1066 was\nhalted after a strategy review under new leadership.\nThe Rights AVXL Purchasers Hold Now\n\nThe complaint asserts claims under Sections 10(b) and 20(a) of the Securities\nExchange Act of 1934. In practical terms, these claims give Class Period\npurchasers a way to seek damages tied to allegedly misleading public\nstatements. Class members do not need to serve as lead plaintiff, or still own\ntheir shares, to remain part of the proposed class.\n\nInvestors with substantial losses may ask the Court to appoint them to oversee\nthe case on behalf of all AVXL purchasers.\n\n\"The timeline raises important questions about when certain risks were known\ninternally versus when they were disclosed to the investing public. Anavex has\nnow stated that its review and certification controls could operate on an\nincomplete information population. Investors who bought AVXL during the Class\nPeriod are entitled to understand what that may mean for them.\" -- Joseph E.\nLevi, Esq.\n\nAct now. Click here to learn more\n(https://edge.prnewswire.com/c/link/?t=0&l=en&o=4791990-14&h=649358680&u=https%3A%2F%2Fsuewallst.com%2Flawsuits%2Fanavex-life-sciences-corp-class-action-lawsuit-avxl%3Fprid%3D210234%26wire%3D4&a=Act+now.+Click+here+to+learn+more)\nor call (888) SueWallSt.\n\nWHY SUEWALLST: SueWallSt is powered by Levi & Korsinsky LLP. Levi &\nKorsinsky LLP has established itself as a nationally-recognized securities\nlitigation firm that has secured hundreds of millions of dollars for aggrieved\nshareholders and built a track record of winning high-stakes cases. The firm\nhas extensive expertise representing investors in complex securities\nlitigation and a team of over 70 employees to serve our clients. For seven\nyears in a row, Levi & Korsinsky has ranked in ISS Securities Class Action\nServices' Top 50 Report as one of the top securities litigation firms in the\nUnited States.\n\nFrequently Asked Questions About the AVXL Lawsuit\n\nQ: Who is eligible to join the AVXL investor lawsuit? A: Investors who\npurchased AVXL stock or securities between November 26, 2025 and August 28,\n2026 and suffered financial losses may be eligible. Eligibility is based on\npurchase date and documented losses -- not on whether you still hold the\nshares.\n\nQ: How much did AVXL stock drop? A: The filed complaint tracks three\nallegedly related stock declines: first of Shares fell $0.02, or about 0.59%\non May 6, 2026, a further $0.18, or 5.55%, on May 12, 2026, and a final $0.19,\nor 6.35%, settling at $2.80 per share on August 31, 2026. Investors who\npurchased shares during the Class Period at allegedly artificially inflated\nprices and suffered losses may be eligible to seek compensation.\n\nQ: What specific misstatements does the AVXL lawsuit allege? A: The complaint\nalleges that Anavex made materially false or misleading statements during the\nClass Period about the effectiveness of its internal control over financial\nreporting, its disclosure controls, and its regulatory risks. According to the\ncomplaint, these statements omitted alleged misconduct by its former CEO.\n\nQ: What is a lead plaintiff and why does it matter? A: A lead plaintiff is\nthe investor appointed by the court to represent the entire class. Lead\nplaintiffs are typically investors with the largest documented losses. Being\nappointed does not increase individual recovery but gives direct oversight of\nhow the case is run.\n\nQ: What happens after I submit my information? A: Your trading history will\nbe reviewed at no cost for an initial assessment of your potential\neligibility.\n\nQ: What if I already sold my AVXL shares -- can I still recover losses? A:\nYes. Eligibility is based on when you purchased, not whether you still hold\nthe shares. Investors who bought during the Class Period and sold at a loss\nmay still be eligible to participate.\n\nQ: Do I need to go to court or give testimony? A: No. The overwhelming\nmajority of class members never appear in court or give depositions. If there\nis a settlement or recovery, eligible class members generally submit a claim\nform to seek their portion.\n\nQ: What does it cost me to participate? A: There is no upfront cost to submit\nyour information and review whether you may be eligible to recover. Should you\nchoose to participate in the securities class action, they are generally\nhandled on a contingency basis, with any attorneys' fees and expenses subject\nto court approval.\n\nCONTACT:\\\nLevi & Korsinsky, LLP\\\nJoseph E. Levi, Esq.\\\n33 Whitehall Street, 27th Floor\\\nNew York, NY 10004\\\njlevi@SueWallSt.com (mailto:jlevi@SueWallSt.com) \\\nTel: (888) SueWallSt\\\nFax: (212) 363-7171\n\nAttorney Advertising. Prior results do not guarantee similar outcomes.\n\nView original content to download\nmultimedia:https://www.prnewswire.com/news-releases/suewallst-reminds-shareholders-of-a-lead-plaintiff-deadline-of-november-30-2026-in-anavex-life-sciences-corp-lawsuit---avxl-302902194.html\n(https://www.prnewswire.com/news-releases/suewallst-reminds-shareholders-of-a-lead-plaintiff-deadline-of-november-30-2026-in-anavex-life-sciences-corp-lawsuit---avxl-302902194.html)\n\nSOURCE SueWallSt.com\n\n\n\nPhoto: \nhttps://mmx.prnewswire.com/media/MS1812443/suewallst-logo-1-Logo.jpg?id=OA2993000\n\nCopyright (c) 2026 PR Newswire Association,LLC. All Rights Reserved."},"type":"article","timestamp":"2026-10-08T14:11:03.065985514Z","server_sent_at_ms":1791468663065},"received_at":"2026-10-08T14:11:03.118Z","source_url":"https://www.prnewswire.com/news-releases/suewallst-reminds-shareholders-of-a-lead-plaintiff-deadline-of-november-30-2026-in-anavex-life-sciences-corp-lawsuit---avxl-302902194.html"},"analysis":{"id":"152990","press_release_id":"164578","analysis_json":{"industry":{"label":"Pharmaceuticals, Biotechnology & Life Sciences","sector":"Health Care"},"redFlags":["company disclosed material weakness in entity-level controls; controls deemed ineffective for four straight period-ends","company told investors to rely only on revised clinical trial descriptions","FDA guidance to be sought on applicability of past efficacy data to ANAVEX 2-73; EMA CHMP Withdrawal Assessment Report referenced","development of ANAVEX 3-71, ANAVEX 1-41, and ANAVEX 1066 halted after strategy review","alleged misconduct by former CEO cited in complaint"],"eventType":"legal_litigation","narrative":"SueWallSt, a Levi & Korsinsky brand, issued a lead-plaintiff-deadline reminder for a securities class action against Anavex Life Sciences (AVXL) filed in the Southern District of New York.\n\nThe proposed class covers purchasers of AVXL securities between November 26, 2025 and August 28, 2026; lead plaintiff applications are due November 30, 2026. The complaint alleges misleading statements about internal control and disclosure control effectiveness, with claims under Sections 10(b) and 20(a) of the Exchange Act.\n\nThis release is law-firm marketing rather than an issuer disclosure; however, the underlying class action reflects real red flags at Anavex, including a disclosed material weakness and halted pipeline programs.","sentiment":"neutral","agentHooks":{"shouldPost":false,"suggestedAngle":"Plaintiff-firm solicitation -- suppress; monitor Anavex's own material-weakness remediation disclosures instead."},"keyFigures":{"customDimensions":{"class_period_end":"August 28, 2026","class_period_start":"November 26, 2025","august_31_2026_close":"$2.80","august_31_2026_decline":"6.35%","lead_plaintiff_deadline":"November 30, 2026"}},"quotedText":"The timeline raises important questions about when certain risks were known internally versus when they were disclosed to the investing public.","namedEntities":{"people":[{"name":"Joseph E. Levi, Esq.","role":"attorney, Levi & Korsinsky / SueWallSt"}],"products":["ANAVEX 2-73","ANAVEX 3-71","ANAVEX 1-41","ANAVEX 1066"],"companies":[{"name":"Anavex Life Sciences Corp.","ticker":"AVXL","relationship":"defendant/issuer named in class action"},{"name":"Levi & Korsinsky LLP","relationship":"plaintiff law firm"},{"name":"SueWallSt","relationship":"plaintiff law-firm brand (powered by Levi & Korsinsky)"},{"name":"FDA","relationship":"regulator referenced"},{"name":"EMA","relationship":"regulator referenced"}],"dollarAmounts":[]},"materialImpact":{"score":1,"reasoning":"Plaintiff law-firm solicitation (Levi & Korsinsky via SueWallSt) reminding investors of a lead plaintiff deadline in an existing securities class action. No new issuer disclosure, no certified class, no settlement."},"tickerRelevance":{"others":[],"primary":"AVXL"},"globalImportance":12,"audienceRelevance":8,"eventTypeSecondary":[],"importanceComponents":{"tickerTier":"micro-cap","eventGravity":"law-firm-solicitation","issuerAuthored":false,"underlyingGovernanceRisk":"elevated (material weakness, former-CEO misconduct allegation)"}},"event_type":"legal_litigation","event_type_secondary":null,"sentiment":"neutral","material_impact_score":1,"narrative":"SueWallSt, a Levi & Korsinsky brand, issued a lead-plaintiff-deadline reminder for a securities class action against Anavex Life Sciences (AVXL) filed in the Southern District of New York.\n\nThe proposed class covers purchasers of AVXL securities between November 26, 2025 and August 28, 2026; lead plaintiff applications are due November 30, 2026. The complaint alleges misleading statements about internal control and disclosure control effectiveness, with claims under Sections 10(b) and 20(a) of the Exchange Act.\n\nThis release is law-firm marketing rather than an issuer disclosure; however, the underlying class action reflects real red flags at Anavex, including a disclosed material weakness and halted pipeline programs.","key_figures":{"customDimensions":{"class_period_end":"August 28, 2026","class_period_start":"November 26, 2025","august_31_2026_close":"$2.80","august_31_2026_decline":"6.35%","lead_plaintiff_deadline":"November 30, 2026"}},"named_entities":{"people":[{"name":"Joseph E. Levi, Esq.","role":"attorney, Levi & Korsinsky / SueWallSt"}],"products":["ANAVEX 2-73","ANAVEX 3-71","ANAVEX 1-41","ANAVEX 1066"],"companies":[{"name":"Anavex Life Sciences Corp.","ticker":"AVXL","relationship":"defendant/issuer named in class action"},{"name":"Levi & Korsinsky LLP","relationship":"plaintiff law firm"},{"name":"SueWallSt","relationship":"plaintiff law-firm brand (powered by Levi & Korsinsky)"},{"name":"FDA","relationship":"regulator referenced"},{"name":"EMA","relationship":"regulator referenced"}],"dollarAmounts":[]},"model_name":"glm-5.3-flashx","prompt_hash":"sha256:5c812bd9e28b810d","schema_hash":"sha256:05005c02d9cffac9","created_at":"2026-10-08T14:11:10.298Z","global_importance":12,"audience_relevance":8,"importance_components":{"tickerTier":"micro-cap","eventGravity":"law-firm-solicitation","issuerAuthored":false,"underlyingGovernanceRisk":"elevated (material weakness, former-CEO misconduct allegation)"}},"durationMs":7147,"modelName":"glm-5.3-flashx"}}